drugset / Trial / NCT01008059
Alfentanil: Simultaneous Testing Pilot
Completed
6 enrolled
Washington University School of Medicine
National Institute of General Medical Sciences (NIGMS) · collab
NaSingle-groupOpen-labelBasic science
Summary
To evaluate two paradigms for simultaneous assessment of hepatic and intestinal CYP3A activity.
Timeline
- Start
- 2009-10
- Primary completion
- 2016-09
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alfentanil | Other / unclassified | 0.5 mg | Intravenous |
| Subject | Alfentanil | Other / unclassified | 1 mg | Intravenous |
| Subject | Alfentanil | Other / unclassified | 4 mg | Intravenous |
Indications
No indication recorded.